Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

577 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).
Rosenthal E, Fougerou-Leurent C, Renault A, Carrieri MP, Marcellin F, Garraffo R, Teicher E, Aumaitre H, Lacombe K, Bailly F, Billaud E, Chevaliez S, Dominguez S, Valantin MA, Reynes J, Naqvi A, Cotte L, Metivier S, Leroy V, Dupon M, Allegre T, De Truchis P, Jeantils V, Chas J, Salmon-Ceron D, Morlat P, Neau D, Perré P, Piroth L, Pol S, Bourlière M, Pageaux GP, Alric L, Zucman D, Girard PM, Poizot-Martin I, Yazdanpanah Y, Raffi F, Pabic EL, Tual C, Pailhé A, Amri I, Bellissant E, Molina JM; ANRS HC31 SOFTRIH Study Group. Rosenthal E, et al. Among authors: dominguez s. HIV Med. 2018 Mar;19(3):227-237. doi: 10.1111/hiv.12571. Epub 2017 Dec 7. HIV Med. 2018. PMID: 29214737 Free article. Clinical Trial.
Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis.
Chalouni M, Pol S, Sogni P, Fontaine H, Lacombe K, Lacombe JM, Esterle L, Dorival C, Bourlière M, Bani-Sadr F, de Ledinghen V, Zucman D, Larrey D, Salmon D, Carrat F, Wittkop L; ANRS CO13 HEPAVIH, ANRS CO22 HEPATHER Cohorts Study Groups; Martinez V. Chalouni M, et al. HIV Med. 2021 Nov;22(10):924-935. doi: 10.1111/hiv.13153. Epub 2021 Aug 17. HIV Med. 2021. PMID: 34402547 Free article.
Cannabis Use and Plasma Human Immunodeficiency Virus (HIV) RNA Levels in Patients Coinfected With HIV and Hepatitis C Virus Receiving Antiretroviral Therapy: Data From the ANRS CO13 HEPAVIH Cohort.
Marcellin F, Miailhes P, Santos M, Mercié P, Di Beo V, Salmon-Céron D, Barré T, Wittkop L, Protopopescu C, Zucman D, Sogni P, Carrieri P; ANRS CO13 HEPAVIH Study Group. Marcellin F, et al. Clin Infect Dis. 2020 Dec 3;71(9):2536-2538. doi: 10.1093/cid/ciaa117. Clin Infect Dis. 2020. PMID: 32055846 No abstract available.
Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Fourati S, Charpentier C, Amiel C, Morand-Joubert L, Reigadas S, Trabaud MA, Delaugerre C, Nicot F, Rodallec A, Maillard A, Mirand A, Jeulin H, Montès B, Barin F, Bettinger D, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Descamps D, Calvez V, Flandre P, Marcelin AG; ANRS AC11 Resistance Study Group. Fourati S, et al. J Antimicrob Chemother. 2015 May;70(5):1507-12. doi: 10.1093/jac/dku535. Epub 2015 Jan 3. J Antimicrob Chemother. 2015. PMID: 25558077 Free article.
Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen.
Raymond S, Nicot F, Pallier C, Bellecave P, Maillard A, Trabaud MA, Morand-Joubert L, Rodallec A, Amiel C, Mourez T, Bocket L, Beby-Defaux A, Bouvier-Alias M, Lambert-Niclot S, Charpentier C, Malve B, Mirand A, Dina J, Le Guillou-Guillemette H, Marque-Juillet S, Signori-Schmuck A, Barin F, Si-Mohamed A, Avettand Fenoel V, Roussel C, Calvez V, Saune K, Marcelin AG, Rodriguez C, Descamps D, Izopet J; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) AC11 Resistance Study Group. Raymond S, et al. Clin Infect Dis. 2018 May 2;66(10):1588-1594. doi: 10.1093/cid/cix1070. Clin Infect Dis. 2018. PMID: 29244143 Free PMC article.
Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France).
Salmon-Ceron D, Cohen J, Winnock M, Roux P, Sadr FB, Rosenthal E, Martin IP, Loko MA, Mora M, Sogni P, Spire B, Dabis F, Carrieri MP; HEPAVIH group. Salmon-Ceron D, et al. BMC Health Serv Res. 2012 Mar 12;12:59. doi: 10.1186/1472-6963-12-59. BMC Health Serv Res. 2012. PMID: 22409788 Free PMC article.
HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patients.
Abravanel F, Raymond S, Pambrun E, Winnock M, Bonnard P, Sogni P, Trimoulet P, Dabis F, Salmon-Ceron D, Izopet J; ANRS CO13 HEPAVIH Study Group. Abravanel F, et al. PLoS One. 2012;7(11):e50289. doi: 10.1371/journal.pone.0050289. Epub 2012 Nov 30. PLoS One. 2012. PMID: 23226258 Free PMC article.
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Joly V, Fagard C, Grondin C, Descamps D, Yazdanpanah Y, Charpentier C, Colin de Verdiere N, Tabuteau S, Raffi F, Cabie A, Chene G, Yeni P; S 130 Apollo Trial Group. Joly V, et al. Antimicrob Agents Chemother. 2013 Feb;57(2):758-65. doi: 10.1128/AAC.01662-12. Epub 2012 Nov 19. Antimicrob Agents Chemother. 2013. PMID: 23165467 Free PMC article. Clinical Trial.
577 results